Portal do Butantan

Turkish Researcher explains the study with CoronaVac that showed 83,5% of the efficacy in healthy people and with comorbidities

Publicado em: 01/01/1970

This Tuesday (7), the first day of the CoronaVac Symposium, the results of the phase 3 clinical studies with Butantan and Sinovac’s vaccine that took place in Turkey were presented. According to the department chief of infectious diseases from the Hacettepe University, Serhat Unal, from 6.559 individuals that were immunized, only 9 had Covid-19 after 14 days or more after the second dose. Among 3.470 people that received placebo, 32 cases were identified. This way, the efficacy of the vaccine was 83,5%. “In front of the comprovation of its efficacy and safety, the CoronaVac has been widely used in Turkey”, reinforced the scientist.

The researchers also analyzed the seroconversion tax (antibodies production) in 1.413 participants (981 vaccinated and 432 of the control group). In the first group, 89,7% of the individuals presented antibodies, against only 4,4% of people that received the placebo - that had asymptomatic infections previously.

In another analysis of immunogenicity, made with 387 participants, 356 (92%) presented neutralizing antibodies. Besides that, high taxes of proliferation of memory’s T cells were identified on vaccinated individuals.

It’s worth pointing out that the study was made with healthy people and with comorbidities too: from 10.214 participants, 1.463 were obese and 6.217 had some king of comordibity, as hypertension and diabetis. Also were part of the study 3.675 professionals from the Health Area, a population highly exposed to the infection.